FDA approves Nerlynx to reduce risk of recurrent breast cancer

The U.S. Food and Drug Administration today approved the use of Nerlynx to treat early-stage HER2-positive breast cancer to lower remission risk.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news